These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 2550842

  • 21. Antagonism of kappa opioid mediated effects in the rat by cyclo(Leu-Gly).
    Bhargava HN, Ramarao P.
    Life Sci; 1989; 45(26):2521-8. PubMed ID: 2559273
    [Abstract] [Full Text] [Related]

  • 22. Binding characteristics of [3H]SCH 23390 in spinal cord and discrete brain regions of kappa-opiate tolerant-dependent and abstinent rats.
    Bhargava HN, Gulati A, Ramarao P.
    Pharmacology; 1991; 42(3):121-7. PubMed ID: 1647533
    [Abstract] [Full Text] [Related]

  • 23. Role of spinal kappa opioid receptors in the blockade of the development of antinociceptive tolerance to morphine.
    Takahashi M, Senda T, Kaneto H.
    Eur J Pharmacol; 1991 Aug 06; 200(2-3):293-7. PubMed ID: 1664330
    [Abstract] [Full Text] [Related]

  • 24. The kappa opioid agonist U-50,488H antagonizes respiratory effects of mu opioid receptor agonists in conscious rats.
    Dosaka-Akita K, Tortella FC, Holaday JW, Long JB.
    J Pharmacol Exp Ther; 1993 Feb 06; 264(2):631-7. PubMed ID: 8382278
    [Abstract] [Full Text] [Related]

  • 25. Effect of chronic administration of U-50,488H, a kappa-opioid receptor agonist, on central dopamine D2 receptors of the rat.
    Veeranna, Reddy PL, Bhargava HN.
    Eur J Pharmacol; 1993 Apr 22; 235(1):23-30. PubMed ID: 8390939
    [Abstract] [Full Text] [Related]

  • 26. Roles of central and peripheral mu, delta and kappa opioid receptors in the mediation of gastric acid secretory effects in the rat.
    Fox DA, Burks TF.
    J Pharmacol Exp Ther; 1988 Feb 22; 244(2):456-62. PubMed ID: 2831341
    [Abstract] [Full Text] [Related]

  • 27. Effects of a kappa-receptor agonist, U-50,488H, on the release of endogenous brain dopamine.
    Clow DW, Jhamandas K.
    Can J Physiol Pharmacol; 1988 Feb 22; 66(2):128-33. PubMed ID: 2836044
    [Abstract] [Full Text] [Related]

  • 28. Antitussive effects of two specific kappa-opioid agonists, U-50,488H and U-62,066E, in rats.
    Kamei J, Tanihara H, Kasuya Y.
    Eur J Pharmacol; 1990 Oct 09; 187(2):281-6. PubMed ID: 2272363
    [Abstract] [Full Text] [Related]

  • 29. Effect of the anticonvulsant U-54494A on cortical neuron excitability: comparison to the kappa agonist U-50488H.
    Ochoa MC, Vogelsang GD, Lum JT, VonVoigtlander PF, Piercey MF.
    Life Sci; 1992 Oct 09; 50(17):1225-33. PubMed ID: 1349150
    [Abstract] [Full Text] [Related]

  • 30. The interaction between kappa-opioid agonist, U-50, 488H, and kainic acid: behavioral and histological assessments.
    Lason W, Simpson JN, McGinty JF.
    Brain Res; 1989 Mar 20; 482(2):333-9. PubMed ID: 2539886
    [Abstract] [Full Text] [Related]

  • 31. A kappa opiate agonist, U50,488H, enhances energy expenditure in rats.
    Mandenoff A, Seyrig JA, Betoulle D, Brigant L, Melchior JC, Apfelbaum M.
    Pharmacol Biochem Behav; 1991 May 20; 39(1):215-7. PubMed ID: 1656474
    [Abstract] [Full Text] [Related]

  • 32. Chronic kappa opioid receptor antagonism produces supersensitivity to U-50,488H at the hypothalamo-pituitary-adrenocortical (HPA) axis level.
    Alcaraz C, Milanés MV, Vargas ML.
    J Pharmacol Exp Ther; 1993 Sep 20; 266(3):1385-9. PubMed ID: 8396634
    [Abstract] [Full Text] [Related]

  • 33. Differential effects of LY235959, a competitive antagonist of the NMDA receptor on kappa-opioid receptor agonist induced responses in mice and rats.
    Bhargava HN, Thorat SN.
    Brain Res; 1997 Feb 07; 747(2):246-51. PubMed ID: 9045999
    [Abstract] [Full Text] [Related]

  • 34. Involvement of kappa-opioid receptor mechanisms in the calcitonin-induced potentiation of opioid effects at the hypothalamus-pituitary-adrenocortical axis.
    Milanés MV, Vargas ML, Martín MI.
    Eur J Pharmacol; 1994 Dec 12; 271(1):103-9. PubMed ID: 7698193
    [Abstract] [Full Text] [Related]

  • 35. Selective kappa opioid agonist for spinal analgesia without the risk of respiratory depression.
    Castillo R, Kissin I, Bradley EL.
    Anesth Analg; 1986 Apr 12; 65(4):350-4. PubMed ID: 3006552
    [Abstract] [Full Text] [Related]

  • 36. Kappa and delta opioid receptor stimulation affects cardiac myocyte function and Ca2+ release from an intracellular pool in myocytes and neurons.
    Ventura C, Spurgeon H, Lakatta EG, Guarnieri C, Capogrossi MC.
    Circ Res; 1992 Jan 12; 70(1):66-81. PubMed ID: 1309318
    [Abstract] [Full Text] [Related]

  • 37. Interaction between the cardiovascular effects of clonidine and the kappa-opioid agonist U-50,488H in the anterior hypothalamic area of the rat brain.
    Verberne AJ, Louis WJ.
    J Pharm Pharmacol; 1989 Feb 12; 41(2):131-3. PubMed ID: 2568424
    [Abstract] [Full Text] [Related]

  • 38. Effects of chronic U50,488H treatment on binding and mechanical responses of the rat hearts.
    Xia Q, Sheng JZ, Tai KK, Wong TM.
    J Pharmacol Exp Ther; 1994 Feb 12; 268(2):930-4. PubMed ID: 8114007
    [Abstract] [Full Text] [Related]

  • 39. Kappa opioid analgesia is dependent on serotonergic mechanisms.
    Vonvoigtlander PF, Lewis RA, Neff GL.
    J Pharmacol Exp Ther; 1984 Nov 12; 231(2):270-4. PubMed ID: 6092612
    [Abstract] [Full Text] [Related]

  • 40. Effect of dizocilpine (MK-801) on analgesia and tolerance induced by U-50,488H, a kappa-opioid receptor agonist, in the mouse.
    Bhargava HN, Thorat SN.
    Brain Res; 1994 Jun 27; 649(1-2):111-6. PubMed ID: 7953621
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.